share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5：募資說明書
美股sec公告 ·  05/09 11:22
Moomoo AI 已提取核心訊息
Allarity Therapeutics Inc. has updated its prospectus supplement, initially filed on November 29, 2023, with a new supplement dated May 9, 2024. This latest filing amends the previous prospectus supplement from March 19, 2024, and relates to the company's At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The amendment follows an increase in Allarity Therapeutics' public float above $75 million as of May 2, 2024, which removes the previous sales limitation under Form S-3. Consequently, the company has revised the Sales Agreement to increase the total offering of common stock to $22 million, inclusive of the $19,633,424 in gross proceeds already raised through the sale of 14,982,765 shares prior to the amendment. The company cautions investors about the high degree of risk involved in investing in its common stock, as detailed in the risk factors section of the prospectus supplement dated March 19, 2024, and other referenced documents.
Allarity Therapeutics Inc. has updated its prospectus supplement, initially filed on November 29, 2023, with a new supplement dated May 9, 2024. This latest filing amends the previous prospectus supplement from March 19, 2024, and relates to the company's At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The amendment follows an increase in Allarity Therapeutics' public float above $75 million as of May 2, 2024, which removes the previous sales limitation under Form S-3. Consequently, the company has revised the Sales Agreement to increase the total offering of common stock to $22 million, inclusive of the $19,633,424 in gross proceeds already raised through the sale of 14,982,765 shares prior to the amendment. The company cautions investors about the high degree of risk involved in investing in its common stock, as detailed in the risk factors section of the prospectus supplement dated March 19, 2024, and other referenced documents.
Alarity Therapeutics Inc.已經更新了最初於2023年11月29日提交的招股說明書補充文件，新增的日期爲2024年5月9日。這份最新文件修訂了自2024年3月19日起的先前招股說明書補充文件，涉及該公司與Ascendiant Capital Markets, LLC簽訂的市場發行銷售協議。該修正案是在截至2024年5月2日將Allarity Therapeutics的公衆持股量增加到7500萬美元以上之後發佈的，這取消了先前在S-3表格下的銷售限制。因此，該公司修訂了銷售協議，將普通股的發行總額增加到2200萬美元，其中包括修訂前通過出售14,982,765股已經籌集的19,633,424美元的總收益。該公司提醒投資者注意投資其普通股所涉及的高度風險，詳見2024年3月19日招股說明書補充文件中的風險因素部分以及其他參考文件。
Alarity Therapeutics Inc.已經更新了最初於2023年11月29日提交的招股說明書補充文件，新增的日期爲2024年5月9日。這份最新文件修訂了自2024年3月19日起的先前招股說明書補充文件，涉及該公司與Ascendiant Capital Markets, LLC簽訂的市場發行銷售協議。該修正案是在截至2024年5月2日將Allarity Therapeutics的公衆持股量增加到7500萬美元以上之後發佈的，這取消了先前在S-3表格下的銷售限制。因此，該公司修訂了銷售協議，將普通股的發行總額增加到2200萬美元，其中包括修訂前通過出售14,982,765股已經籌集的19,633,424美元的總收益。該公司提醒投資者注意投資其普通股所涉及的高度風險，詳見2024年3月19日招股說明書補充文件中的風險因素部分以及其他參考文件。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息